Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Latest developments in PTCL treatment

Marta Rodriguez-Moreno • 11 Oct 2021
EORTC CLTF 2021
Lymphoma Non-Hodgkin Lymphoma Peripheral T-Cell Lymphoma Rare Diseases

Marta Rodriguez-Moreno, Instituto de Investigación Sanitaria, Fundación Jiménez Díaz University Hospital, Madrid, Spain, talks on recent research in peripheral T-cell lymphoma (PTCL), highlighting efforts to personalize treatments for patients with PTCL through the identification of new biomarkers. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Marta Rodriguez-Moreno

0:38
Prognostic factors for AITL
Marta Rodriguez-Moreno • 11 Oct 2021
4:24
Risk stratification of patients with PTCL using molecular profiling
Marta Rodriguez-Moreno • 11 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals